Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Cyclacel Pharma (CYCC) Reports Q2 Loss of $1.19
August 10, 2016 4:12 PM EDTCyclacel Pharma (NASDAQ: CYCC) reported Q2 EPS of ($1.19), versus ($1.01) reported last year. Revenue for the quarter came in at $296 thousand, versus $222 thousand reported last year.
For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.
... More